NCT01815515View on ClinicalTrials.gov

Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

November 18, 2015

Conditions
Metastatic Prostate Cancer
Interventions
DRUG

18F-DCFBC

"18F-DCFBC is a radiofluorinated small-molecule inhibitor of prostate-specific membrane antigen (PSMA).~A bolus of 10 mCi (370 MBq) \[9-11 mCi (333-407 MBq)\] of 18F-DCFBC will be injected into the IV line by slow IV push."

Trial Locations (1)

21287

Johns Hopkins University, Baltimore

All Listed Sponsors
lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT01815515 - Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter